MaximBio, a Maryland-based manufacturer specializing in lateral flow and diagnostic devices, received a $49.5 million award designated to help fortify their domestic manufacturing capabilities for diagnostic testing and enhance preparedness for potential future pandemics.
This funding came from the U.S. Department of Health and Human Services (HHS) through the Administration for Strategic Preparedness and Response (ASPR), MaximBio says. The award is part of a broader initiative awarding $600 million to 12 domestic COVID test manufacturers.
The funding from ASPR underscores MaximBio’s commitment to advancing public health and strengthening the domestic supply chain, the company says.
Further reading: Lab Volume Index Delivers Insights on Post-Pandemic Diagnostic Testing
“This significant investment will enable us to maintain our U.S. operations for diagnostic test manufacturing,” says Jonathan Maa, chief operating officer at MaximBio. “We are proud to be playing a crucial role in the nation’s response to the ongoing health crises and fortifying our defenses against potential future pandemics.”
This strategic funding aligns with the company’s commitment to contribute to the well-being of the nation’s diagnostic infrastructure.
MaximBio is a provider in lateral flow and diagnostic device manufacturing, dedicated to providing innovative solutions for the detection and diagnosis of various health conditions, the company says.
Featured image: MaximBio ClearDetect COVID-19 Antigen Home Test, 2-Test Pack. Photo: MaximBio
